Lynes John, Flores-Milan Gabriel, Rubino Sebastian, Arrington John, Macaulay Robert, Liu James K C, Beer-Furlan Andre, Tran Nam D, Vogelbaum Michael A, Etame Arnold B
Division of Neurosurgery, Moffitt Cancer Center, Tampa, FL, United States.
Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States.
Front Oncol. 2022 Aug 12;12:962702. doi: 10.3389/fonc.2022.962702. eCollection 2022.
Meningiomas are the most common intracranial primary tumor in adults. Surgery is the predominant therapeutic modality for symptomatic meningiomas. Although the majority of meningiomas are benign, there exists a subset of meningiomas that are clinically aggressive. Recent advances in genetics and epigenetics have uncovered molecular alterations that drive tumor meningioma biology with prognostic and therapeutic implications. In this review, we will discuss the advances on molecular determinants of therapeutic response in meningiomas to date and discuss findings of targeted therapies in meningiomas.
脑膜瘤是成人最常见的颅内原发性肿瘤。手术是有症状脑膜瘤的主要治疗方式。尽管大多数脑膜瘤是良性的，但仍有一部分脑膜瘤具有临床侵袭性。遗传学和表观遗传学的最新进展揭示了驱动脑膜瘤生物学行为的分子改变，这些改变具有预后和治疗意义。在本综述中，我们将讨论迄今为止脑膜瘤治疗反应分子决定因素的进展，并探讨脑膜瘤靶向治疗的研究结果。
